Finally, taking advantage of a Gna11-mutant syngeneic model of melanoma, we tested the combination of VS-4718 + darovasertib and observed a significant reduction in tumor burden with the combination treatment (Figures S5A−S5D).49 This evidence concerns the gene GNA11 and neoplasm.